Clinical Trial Update: A Study of Real-World Treatment Patterns and Outcomes Among HR+/HER2- Metastatic Breast Cancer Patients Treated With First-Line CDK4/6 Inhibitors

View source ↗

Summary

A completed real-world study sponsored by Novartis examines how first-line CDK4/6 inhibitors are used and the outcomes in HR+/HER2- metastatic breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• KISQALI (ribociclib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Breast Cancer | Status: COMPLETED